Back to Search
Start Over
Current issues in prophylactic therapy for persons with hemophilia.
- Source :
-
Acta haematologica [Acta Haematol] 2006; Vol. 115 (3-4), pp. 162-71. - Publication Year :
- 2006
-
Abstract
- Factor VIII or IX replacement in a prophylactic manner is utilized for many patients with moderate to severe hemophilia A or B. Studies have shown it to be effective in reducing or preventing degenerative joint disease in many but not all patients. However, many unanswered questions still exist and optimization of this expensive treatment regimen is needed. This paper recounts the current products that are available for use and explores the literature regarding different treatment regimens. It explores age at initiation, dose, interval between infusions, joint health outcomes, barriers to compliance and age at discontinuation of prophylaxis. Individualized treatment is recommended. Collaborative efforts are needed to improve outcomes for all persons with hemophilia.<br /> (Copyright 2006 S. Karger AG, Basel)
- Subjects :
- Adolescent
Adult
Chemoprevention economics
Chemoprevention trends
Child
Child, Preschool
Coagulants economics
Factor IX economics
Factor IX therapeutic use
Factor VIII economics
Factor VIII therapeutic use
Female
Hemophilia A complications
Hemophilia A economics
Hemophilia B complications
Hemophilia B economics
Hemorrhage economics
Hemorrhage etiology
Humans
Male
Treatment Outcome
Coagulants therapeutic use
Hemophilia A drug therapy
Hemophilia B drug therapy
Hemorrhage prevention & control
Subjects
Details
- Language :
- English
- ISSN :
- 0001-5792
- Volume :
- 115
- Issue :
- 3-4
- Database :
- MEDLINE
- Journal :
- Acta haematologica
- Publication Type :
- Academic Journal
- Accession number :
- 16549891
- Full Text :
- https://doi.org/10.1159/000090930